Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment
Purpose. To investigate the effectiveness of mineralocorticoid receptor (MR) antagonist in patients with steroid-induced central serous chorioretinopathy (CSC). Methods. A retrospective review was conducted of steroid-induced CSC patients who were treated with the MR antagonist spironolactone 50 mg...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/4258763 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549522850447360 |
|---|---|
| author | Jin Young Kim Ju Byung Chae Jisoo Kim Dong Yoon Kim |
| author_facet | Jin Young Kim Ju Byung Chae Jisoo Kim Dong Yoon Kim |
| author_sort | Jin Young Kim |
| collection | DOAJ |
| description | Purpose. To investigate the effectiveness of mineralocorticoid receptor (MR) antagonist in patients with steroid-induced central serous chorioretinopathy (CSC). Methods. A retrospective review was conducted of steroid-induced CSC patients who were treated with the MR antagonist spironolactone 50 mg once per day for at least 1 month. The primary outcome measure was complete resolution rate of subretinal fluid (SRF) after spironolactone treatment. Secondary outcomes included central subfield thickness (CST), subfoveal choroidal thickness (SFCT), and best-corrected visual acuity (BCVA) changes after spironolactone treatment. Results. Seventeen eyes from 15 patients were included in this study. Conditions warranting chronic systemic steroid use were myasthenia gravis (6/15, 40%), glomerulonephritis (5/15, 33.3%), and organ transplantation (4/15, 26.7%). Mean symptom duration of CSC was 4.00 ± 3.04 months. After spironolactone treatment, 14 eyes (82.4%) showed complete resolution of SRF (P<0.001) without discontinuation of systemic steroid. CST and BCVA were significantly improved after spironolactone treatment. SFCT was significantly decreased after spironolactone treatment. No patients experienced electrolyte imbalance after spironolactone treatment. Conclusion. MR antagonist treatment may be a therapeutic option for steroid-induced CSC patients. This treatment modality may be especially beneficial for steroid-induced CSC patients who cannot discontinue steroid medication due to systemic conditions. |
| format | Article |
| id | doaj-art-73e2b34e17e14270b254ba5ba4d8c6f2 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-73e2b34e17e14270b254ba5ba4d8c6f22025-02-03T06:11:03ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/42587634258763Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid TreatmentJin Young Kim0Ju Byung Chae1Jisoo Kim2Dong Yoon Kim3Department of Ophthalmology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Republic of KoreaDepartment of Ophthalmology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Republic of KoreaDepartment of Ophthalmology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Republic of KoreaDepartment of Ophthalmology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Republic of KoreaPurpose. To investigate the effectiveness of mineralocorticoid receptor (MR) antagonist in patients with steroid-induced central serous chorioretinopathy (CSC). Methods. A retrospective review was conducted of steroid-induced CSC patients who were treated with the MR antagonist spironolactone 50 mg once per day for at least 1 month. The primary outcome measure was complete resolution rate of subretinal fluid (SRF) after spironolactone treatment. Secondary outcomes included central subfield thickness (CST), subfoveal choroidal thickness (SFCT), and best-corrected visual acuity (BCVA) changes after spironolactone treatment. Results. Seventeen eyes from 15 patients were included in this study. Conditions warranting chronic systemic steroid use were myasthenia gravis (6/15, 40%), glomerulonephritis (5/15, 33.3%), and organ transplantation (4/15, 26.7%). Mean symptom duration of CSC was 4.00 ± 3.04 months. After spironolactone treatment, 14 eyes (82.4%) showed complete resolution of SRF (P<0.001) without discontinuation of systemic steroid. CST and BCVA were significantly improved after spironolactone treatment. SFCT was significantly decreased after spironolactone treatment. No patients experienced electrolyte imbalance after spironolactone treatment. Conclusion. MR antagonist treatment may be a therapeutic option for steroid-induced CSC patients. This treatment modality may be especially beneficial for steroid-induced CSC patients who cannot discontinue steroid medication due to systemic conditions.http://dx.doi.org/10.1155/2018/4258763 |
| spellingShingle | Jin Young Kim Ju Byung Chae Jisoo Kim Dong Yoon Kim Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment Journal of Ophthalmology |
| title | Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment |
| title_full | Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment |
| title_fullStr | Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment |
| title_full_unstemmed | Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment |
| title_short | Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment |
| title_sort | mineralocorticoid receptor antagonist treatment for steroid induced central serous chorioretinopathy patients with continuous systemic steroid treatment |
| url | http://dx.doi.org/10.1155/2018/4258763 |
| work_keys_str_mv | AT jinyoungkim mineralocorticoidreceptorantagonisttreatmentforsteroidinducedcentralserouschorioretinopathypatientswithcontinuoussystemicsteroidtreatment AT jubyungchae mineralocorticoidreceptorantagonisttreatmentforsteroidinducedcentralserouschorioretinopathypatientswithcontinuoussystemicsteroidtreatment AT jisookim mineralocorticoidreceptorantagonisttreatmentforsteroidinducedcentralserouschorioretinopathypatientswithcontinuoussystemicsteroidtreatment AT dongyoonkim mineralocorticoidreceptorantagonisttreatmentforsteroidinducedcentralserouschorioretinopathypatientswithcontinuoussystemicsteroidtreatment |